Tanabe Pharma America Finalizes RADICAVA Transfer to Shionogi

Tanabe Pharma Remains Focused on Rare Disease Innovation and Unmet Patient Needs

Apr. 2, 2026 at 7:24am

Got story updates? Submit your updates here. ›

Tanabe Pharma America, Inc. (TPA) has finalized the transfer of the RADICAVA (edaravone) business, including intellectual property rights and marketing rights, to Shionogi Inc. (SI). This strategic move supports the long-term growth and sustainability of the ALS treatment by solidifying its future within a company recognized for its commitment to innovative medicines.

Why it matters

The transfer allows TPA to sharpen its focus on advancing a promising pipeline of assets and core therapeutic areas, including treatments addressing significant unmet medical needs. Patients can expect continuity in product availability and support services as the transition is designed to minimize disruption to their care.

The details

Effective immediately, the RADICAVA business has officially transitioned to SI. For certain countries and regions, rights will be transferred sequentially following the prescribed procedures. There will be no changes to the current supply chain, and all established patient support services will remain fully operational and accessible. The process to report adverse events relating to RADICAVA will also remain unchanged.

  • The transfer was previously announced on December 22, 2025.
  • The finalization of the transfer occurred on April 1, 2026.

The players

Tanabe Pharma America, Inc. (TPA)

The wholly owned subsidiary of Tanabe Pharma Corporation that was established to develop and advance the company's pipeline as well as commercialize approved pharmaceutical products in North America.

Shionogi Inc. (SI)

The company that has acquired the RADICAVA business, including intellectual property rights and marketing rights, from TPA.

Got photos? Submit your photos here. ›

What they’re saying

“We are incredibly proud of the achievements we have accomplished in bringing RADICAVA to patients living with ALS, and today marks both a meaningful milestone and an exciting new beginning.”

— Yasutoshi Kawakami, President, Tanabe Pharma America, Inc.

The takeaway

This strategic move strengthens Tanabe Pharma's financial foundation and allows the company to sharpen its focus on advancing a promising pipeline of assets and core therapeutic areas, including treatments addressing significant unmet medical needs for patients.